Latest Headlines

Latest Headlines

Agenus inks Oncophage cancer vaccine deal with Russian company

Cancer vaccine developer Agenus has inked a licensing, development and manufacturing technology transfer agreement with Russian drug company NewVac. Under the deal, NewVac gets to manufacture, market...

Antigenics shares gain on GSK's ambitious PhIII vax program

GlaxoSmithKline isn't the only company cheering this week's launch of a late-stage program for a shingles vaccine. Antigenics flagged its own role in the parade for the potential blockbuster and was

Antigenics says FDA 'too rigid' to approve Oncophage

Antigenics has spent hundreds of millions of dollars on the late-stage development of the cancer vaccine Oncophage, but its CEO tells Mass High Tech that the FDA's mindset on cancer drug development

Antigenics shares plunge on Oncophage rejection

Antigenics (AGEN) has a fresh round of sour news to report this morning, announcing that European regulators will soon formally reject its kidney cancer vaccine Oncophage. The biotech said that it

Tiny Antigenics gears up to market cancer vaccine

After spending 12 years and $425 millions of dollars in a so far unsuccessful quest to win FDA approval of Oncophage, tiny

Antigenics gets world's first cancer vaccine approval

Russia has improbably emerged as a world leader in new cancer vaccines. The country's regulatory body approved the use of